SeaPRwire
Read More

Recipients of Sinovac Covid-19 vaccine not exempted from pre-event testing: MOH

aseanpr
5 minutes

SINGAPORE - People who have received the Sinovac Covid-19 vaccine will not be exempted from pre-event testing, said the Ministry of Health (MOH) on Wednesday (June 30). Vaccines not included in Singapore's national vaccination programme - Sinovac's among them - may lack sufficient documentation of how effective they are at protecting against Covid-19 infection, and in particular against the Delta variant of the virus currently circulating, said MOH. The Delta strain is a new mutation of the coronavirus that is more infectious. "Hence, from the public health point of view, individuals vaccinated with vaccines other than those in our Covid-19 national vaccination programme will still have to undergo pre-event testing," said MOH. The Government previously said that those who are fully vaccinated are exempt from pre-event testing before attending events such as live performances, Mice events, and wedding solemnisations. Authorities gave approval last month to 24 private healthcare clinics to draw on the Government's existing stock of the Sinovac vaccine. Dr Leong Hoe Nam of Rophi Clinic told The Straits Times on Wednesday that his clinic has administered more than 400 doses of the Sino...

ACN Newswire
Read More

China Huarong’s “Recent Concerns” and “Future Worries”

indie
8 minutes

HONG KONG, Jun 30, 2021 - (ACN Newswire via SEAPRWire.com) - (This article is reprinted from Gelonghui) Since China Huarong announced the postponement of its 2020 results, several international rating agencies have downgraded its corporate and bond ratings. On June 2, S&P Global Ratings announced that it would continue to keep its "BBB+" long-term and "A-2" short-term issuer credit ratings on China Huarong Asset Management Co. Ltd. (CHAMC) and its subsidiaries, China Huarong Financial Leasing Co. Ltd. (HRFL) and China Huarong International Holdings Ltd. (Huarong International) on CreditWatch with negative implications; The "BBB+" long-term issue rating on the notes that Huarong International guarantees also remained on CreditWatch with negative implications.Cash and cash equivalentsCNY00'million China Huarong (2799.HK) - GSD. Cash Flow Statement / Net cash flow generated from operating activitiesHowever, S&P Global Ratings continued to view CHAMC as a government-related entity with a very high likelihood of extraordinary government support. The reasons of remaining to be listed on CreditWatch with negative implications were the uncertainty caused by China Huarong's delay in...

SeaPRwire
Read More

Stage 2 of Thomson-East Coast MRT Line to open on Aug 28

aseanpr
2 minutes

SINGAPORE - The long-awaited second stage of the Thomson-East Coast MRT Line will start running on Aug 28. Transport Minister S. Iswaran on Wednesday (June 30) said the new six-station stretch - connecting Springleaf, Lentor, Mayflower, Bright Hill, Upper Thomson and Caldecott stations - "would not have been possible without the hard work, adaptability and personal sacrifices of our technicians, engineers and ground staff". Delayed in part by the Covid-19 pandemic, TEL2 will have two interchanges - Caldecott with the Circle Line and Bright Hill with the future Cross Island Line. Mr Iswaran said the TEL will enhance the resilience of the rail network. When fully opened in the latter half of the decade, the TEL will interchange with five existing MRT lines (North-south, East-west, North-east, Circle and Downtown) as well as the Cross Island Line. When TEL is fully completed, more than 240,000 current and future households will be within a 10-minute walk from a station along the line, he added. Walkthrough of Caldecott Station (Thomson-East Coast Line) TEL1 and TEL2 alone will benefit about 100,000 households, he said. The first stage of the TEL - a three-station stretch from Woodland...

ACN Newswire
Read More

爱高公布2020/21全年业绩 笔记本电脑品牌业务于充满挑战的环境中蓬勃发展

tallulah
1 minute

HONG KONG, Jun 30, 2021 - (亚太商讯 via SEAPRWire.com) - 爱高集团（「爱高」或「集团」; 股份代号: 00328），一家具国际领导地位的电子产品制造商，宣布其截至2021年3月31日（「回顾年内」）之全年业绩。尽管新冠肺炎疫情的来袭让2020年充满挑战，但笔记本电脑需求强劲，集团的营业额录得33%的增幅至12.79亿港元（2020年：9.61亿港元）。其中，笔记本电脑的销售额录得6.32亿港元，较去年同期增长261%（2020年：1.75亿港元），销量超过20万部，彰显爱高旗下的笔记本电脑品牌广为消费者接受及欢迎。回顾年内，集团毛损率改善1.9个百分点至-4.8%（2020年：-6.7%），本公司股东应占期内亏损情况改善40%至3.6亿港元（2020年：5.99亿港元）。由于受到全球各类电子零件供应短缺、供货商无法及时交付关键零件的负面影响，回顾年内部分的销售订单被迫放弃。犹幸回顾年内生产的笔记本电脑数量大幅增加，本公司股东应占期内亏损情况亦有所改善。基于同样原因，固定成本（即制造设施、广告及品牌推广，以及产品制造及开发的成本）已被摊薄，而其中值得一提的是，集团在原材料成本的谈判中，具有较优胜的议价能力。回顾年内，爱高继续坚持其长远增长策略，专注于发展及推广AVITA 品牌的笔记本电脑。与此同时，集团亦紧贴市场趋势，继续开发多款时尚的笔记本电脑产品，以及针对位于尚未普及无线网络之市场和国家的私人家庭而推出支持LTE功能的平板计算机。新冠肺炎疫情之下，全球数十亿人进入了全新的生活模式，在家工作成为新常态，笔记本电脑及平板计算机亦因此受惠。爱高主席兼行政总裁梁伟成先生表示：「我们的笔记本电脑销售能够录得261%的激增，着实令人鼓舞，亦足证我们成功转型至发展笔记本电脑品牌业务。集团锐意迈进笔记本电脑领域，投入更多资源发展业务，不断强化品牌及调整产品组合。自动化及机械化生产是爱高目前另一投资领域，以便满足笔记本电脑日益增长的市场需求。对于有关旗下AVITA笔记本电脑的未来发展方向，我们审慎乐观地认为集团的笔记本电脑销售量将有望超过每年100万台。此外，我们将于明年庆祝上市30周年，我们认为此亦是集团追寻新路向，以推动爱高未来数十年增长的最佳时机。因此，我们正努力物色符合新兴技术趋势的投资机遇，如物联网产品、5G设备、边缘运算甚至是电动汽车。尽管营商环境挑战与日俱增，但我们坚信，凭借集团的不懈耕耘，管理层的丰富经验，以及集团良好的品牌声誉，我们现时立于优势，并准备就绪面对重重挑战的营商环境，保持发展势头。」关于爱高集团 (股份代号: 00328)成立于1968年，爱高集团是一家具国际领导地位的电子产品制造商。集团于 1992 年在香港联交所上市，凭借其在制造、营运与研发等方面的核心实力，以及对质量的坚持，多年来不断茁壮成...

ACN Newswire
Read More

Alco Announces 2020/21 Annual Results, Notebook Computer Brand Business Thriving Amid Challenging Environment

indie
4 minutes

HONG KONG, Jun 30, 2021 - (ACN Newswire via SEAPRWire.com) - Alco Holdings Limited ("Alco" or the "Group"; stock code: 00328), a world-leading manufacturer of electronic products, announced its annual results for the year ended 31 March 2021 (the "Year").Year 2020 was challenging due to the COVID-19 pandemic, nonetheless, with notebook computers in strong demand, the Group recorded a 33% increase in turnover to HK$1,279 million (2020: HK$961 million). Notebook computer sales were HK$632 million, representing 261% year-on-year growth (2020: HK$175 million), with sales volume near a quarter million units, evidencing the popularity and consumer acceptance of Alco's notebook computer brands.During the Year, the Group's gross loss margin improved by 1.9 percentage points to -4.8% (2020: -6.7%), and net loss attributable to equity holders of the Company improved by 40% to HK$360 million (2020: HK$599 million). Certain sales orders were abandoned during the Year compelled by the global supply shortage of various electronic parts and components, and suppliers unable to timely deliver critical components, as such the Group's profitability was affected. Nevertheless, net loss attributable to...

ACN Newswire
Read More

医思健康公布2020/21年度全年业绩

tallulah
1 minute

HONG KONG, Jun 30, 2021 - (亚太商讯 via SEAPRWire.com) - 香港最大非医院医疗服务机构* ── 医思健康（「公司」，连同附属公司，总称「集团」；香港联交所股份编号：2138）公布截至2021年3月31日止财政年度（「年内」）之全年业绩。业绩摘要-- 引入郑志刚博士、高盛亚洲、冠君产业信托等多名策略性股东-- 医疗服务收入飙升54.0%至9.60亿港元﹐占总收入比重上升至46.1%-- 中国内地收入升52.5% 至1.35亿港元-- 下半年总收入较上半年飙升61.0%，下半年税后盈利较上半年飙升223.2%-- 息税折旧及摊销前之盈利为3.97亿港元，税后盈利为2.26亿港元，每股基本盈利18.8港仙-- 拟派末期股息每股12.9港仙（连同中期股息3港仙，全年共派发股息15.9港仙），全年派息比率为84.6%-- 于2021年3月31日，集团在香港、中国内地及澳门增至139名全职专属注册医生，联网医生超500名-- 于2021年3月31日，集团之总服务占地面积升32%至398,000平方呎回顾年内，尽管新型冠状病毒疫情为全球经济带来前所未有的挑战，逆境之下医思健康再次展现业务韧性，维持稳健的表现。在富有执行力的管理层的领导下，集团迅速采取有效措施，积极应对市场变化，并把握发展及投资机会强化集团的优势。集团透过主动与客户互动及加强电子商务活动，推动香港本地市场及中国内地的销售。年内收购了多间医疗机构，又致力促进不同医疗专科之间的交叉销售，打造独有的闭环生态系统，扩大集团于健康医疗服务市场份额，巩固行业领先地位。受惠于集团的医疗资产整合策略及市场对医疗服务的刚性需求，在封关导致缺少访港医疗旅客的情况下，集团的医疗服务收入仍按年大幅上升54.0% 至9.60亿港元，医疗服务的收入占总收入的比重上升14.1个百分点至46.1%，中国内地收入升52.5% 至1.35亿港元，带动总收入增长6.8%至20.80亿港元, 其中下半年的增长势头强劲，下半年总收入较上半年飙升61.0%，下半年税后盈利较上半年飙升223.2%。集团税后盈利为2.26亿港元，每股基本盈利18.8港仙。撇除自持物业、厂房及设备的息税折旧及摊销﹐较能准确反映集团盈利能力的息税折旧及摊销前之盈利为3.97亿港元。集团拟派末期股息每股12.9港仙（连同中期股息3港仙，全年共派发股息15.9港仙），全年派息比率为84.6%。强大的融资能力及出众的并购执行力为抢占市场先机，加快布局具潜力的业务板块及拓展大湾区市场，集团引入多名策略性股东(详见下图)，足见集团卓越的融资能力。 其中，集团于 2021年4月，透过配售股份引入新世界发展有限公司（香港联交所股份编号：17）执行副主席兼行政总裁郑志刚博士为策略性股东，预期将助力集团实践医疗地产化策略，为集团引入策略性物业与房...

ACN Newswire
Read More

EC Healthcare Announces FY2020/21 Annual Results

indie
8 minutes

HONG KONG, Jun 30, 2021 - (ACN Newswire via SEAPRWire.com) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong, announces today its annual results for the fiscal year ended 31 March 2021 (the "Year").Business Highlights -- Introduced numerous strategic shareholders including Dr. Cheng Chi Kong, Goldman Sachs Asia, Champion REIT, etc. -- Revenue from medical services surged 54.0% to HK$960 million, with its contributions to total revenue rose to 46.1%-- Revenue in the Mainland China increased by 52.5% to HK$135 million-- Second-half total revenue jumped 61.0% versus first half, second-half profit after tax surged by 223.2% versus first half-- Earnings before interest, taxes, depreciation, and amortization ("EBITDA") amounted to HK$397 million, profit after tax was HK$226 million and basic earnings per share were 18.8 HK cents-- The board of directors (the "Board") proposed final cash dividend of 12.9 HK cents per share, which together with the interim dividend of 3 HK cents per share, will bring the total annual dividend to 15.9 HK cents per share, representing...

SeaPRwire

Singapore inks deal with GSK to purchase Covid-19 drug sotrovimab

aseanpr
3 minutes

SINGAPORE (THE BUSINESS TIMES) - Singapore has inked a deal with drugmaker GlaxoSmithKline Singapore and clinical-stage immunology firm Vir Biotechnology for the supply of a medication for patients with mild to moderate Covid-19. The advance purchase agreement is for the supply of sotrovimab, an investigational single-dose monoclonal antibody administered through intravenous infusion, GSK Singapore said in a statement on Wednesday (June 29). It is used to treat Covid-19 patients who do not need supplemental oxygen but are at risk of progressing to severe disease. Sotrovimab is currently undergoing regulatory review by the Health Sciences Authority for interim authorisation under the Pandemic Special Access Route (PSAR), GSK Singapore said. The medication was, on May 26, granted emergency-use authorisation by the United States Food and Drug Administration; the European Medicines Agency's Committee for Medicinal Products for Human Use has also issued a positive scientific opinion. The British drugmaker's PSAR application includes data from an interim analysis of efficacy and safety data from its phase three trial, which it said was stopped early by an independent data-monitoring comm...

ACN Newswire
Read More

Market Selloff Presents Good Opportunity to Accumulate ETH While It is Undervalued Says PrimeXBT Analyst Kim Chua

indie
7 minutes

US, Jun 30, 2021 - (ACN Newswire via SEAPRWire.com) - News flows the past week has centred around BTC's big flash dip and about how long-term investors are taking the chance to accumulate more BTC. However, no one seems to be talking about the second largest coin, ETH. Is ETH a good buy at these levels?The rise in DeFi is the single largest contributor towards the demand for ETH in this bull run as ETH is used both as a collateral as well as a fuel to use the ETH blockchain for yield-farming. While other developments like NFTs also contribute to the popularity of ETH, by and large, 90% of the demand for ETH has been for DeFi usage so far. Thus, to study if ETH is a worthwhile investment now, our focus should still be on DeFi, specifically, the trend about DeFi going forward.ETH, while being the undisputed leader in DeFi, has seen some competition from other blockchains like Binance Smart Chain (BSC) and Polygon (MATIC). Part of the argument against ETH in DeFi use has been its high gas fee and slow speed, which has caused both yield-farmers and protocols to migrate to other cheaper blockchains like BSC and Polygon (MATIC). This resulted in some value from the ETH blockchain moving ...

SeaPRwire

Didi prices US IPO at top of range to raise more than $5.4 billion

elean
4 minutes

HONG KONG (BLOOMBERG) - Chinese ride-hailing giant Didi Global Priced shares in its US initial public offering at the top of a marketed range to raise at least US$4 billion (S$5.4 billion) and will likely add to that sum by expanding the size of the share sale, according to people familiar with the matter. Didi, which planned to sell 288 million American depositary shares, priced them at US$14 each on Tuesday (June 29) after marketing them for US$13 to US$14, said the people, who asked not to be identified because the details weren't public yet. A final decision hasn't been made on increasing the number of shares being sold, the people said. A representative for Didi declined to comment. At US$14 a share, the IPO would raise more than US$4 billion before any increase in the number of shares, making it the second largest US IPO by a Chinese company on record, after Alibaba Group Holding's US$25 billion debut in 2014, according to data compiled by Bloomberg. The IPO shows investors are backing Didi despite Beijing's scrutiny of Chinese internet firms, which has stoked uncertainty ahead of its debut. The price would give Didi a market value of about US$67 billion, based on the outstan...

SeaPRwire
Read More

Morning Briefing: Top stories from The Straits Times on June 30

aseanpr
2 minutes

Good morning! Here are our top stories to kick-start your Wednesday, June 30. 3 new Covid-19 cases linked to Changi General Hospital cluster The number of new cases in the community has fallen from 104 cases two weeks ago to 76 in the past week. READ MORE HERE MOH to stop giving details of Covid-19 community cases It will instead detail the progress in the nationwide vaccination scheme, in addition to daily case numbers. READ MORE HERE Six medical centres for migrant workers in new healthcare system to come The new system will be rolled out to provide primary healthcare to the workers and reduce the risk of disease outbreaks. READ MORE HERE More on this topic Related Story ST newsletters: Get alerts on the latest news Countries that open too quickly before high vaccine coverage will see Covid-19 spikes: Lawrence Wong More people may be hospitalised or even die of the virus, he noted, adding that Singapore is trying to avoid such a situation. READ MORE HERE Malls in Singapore roll out SafeEntry Gateway boxes for checking out The boxes for checking out feature a blue sticker to differentiate them from those for checking in. READ MORE HERE Underpaid and overworked, Malaysia's contract...

SeaPRwire

Elon Musk to invest up to $40 billion in his Starlink satellite Internet service

elean
3 minutes

BARCELONA (REUTERS) - Billionaire entrepreneur Elon Musk said on Tuesday (June 29) he plans to invest up to US$30 billion (S$40.4 billion) to develop his ambitious Starlink satellite Internet service. Starlink plans to deploy thousands of low-orbit satellites to provide high-speed Internet to isolated and poorly connected areas. It has so far deployed over 1,500 satellites and by August it will be able to provide coverage everywhere in the world except the North and South Poles, Mr Musk told the Mobile World Congress, a telecoms industry conference underway in Barcelona, by video. The Tesla chief said he expects to invest "at least five billion dollars, and maybe as much as ten billion" in Starlink before the service has a positive cash flow. "Then over time it is going to be a multiple of that, and that would be 20 or 30 billion dollars. It is a lot basically," he added. Starlink is currently operating in about a dozen countries, with more being added, and it currently has just over 69,000 active users, Mr Musk said. "We are on our way, I think, to having a few hundred thousand users, possibly over 500,000 users, within 12 months," he added. "There is a need for connectivity in pl...

SeaPRwire

South Africa to tighten oversight of crypto assets after series of scams

elean
3 minutes

JOHANNESBURG (BLOOMBERG) - South Africa is moving with more urgency to stiffen oversight of cryptocurrency assets after a proliferation of scams. A new regulatory timeline foresees finalising a framework in three to six months, after the publication of proposals earlier in June that requires public comment before approval, according to Mr Kuben Naidoo, chief executive officer of South Africa's banking regulator known as the Prudential Authority. "We are trying to put in place the regulatory framework quickly," said Mr Naidoo, who's also a deputy governor of the South African central bank. "Defining this as a financial product and then developing the regulatory framework is important." The approach that's taking shape means tougher rules could be imminent this year after a jolt of scandals that most recently included a suspected Ponzi scheme, which resulted in the disappearance of an estimated US$3.6 billion (S$4.8 billion) in bitcoin. South African cryptocurrency service providers have been operating unchecked by regulatory powers even as the popularity of the asset class has taken off. Last year, the collapse of Johannesburg-based Mirror Trading International was called the bigges...

SeaPRwire

Tom Brady, Gisele Bündchen take stake in crypto exchange FTX

elean
4 minutes

NEW YORK (BLOOMBERG) - Celebrity couple Tom Brady and Gisele Bundchen have taken an equity stake in cryptocurrency exchange FTX as part of a long-term partnership, marking the duo's newest foray into the world of digital assets. Both Mr Brady, a celebrated American football player, and Ms Bundchen, a world-renowned supermodel, will serve as ambassadors for FTX, according to an announcement on Tuesday (June 29). The cryptocurrency exchange declined to disclose their equity stake, but did say they will both receive an unspecified amount and type of crypto. Ms Bundchen will also take on the role of FTX's environmental and social-initiatives adviser, according to the release. "Tom and Gisele are both legends and they both reached the pinnacle of what they do," Mr Sam Bankman-Fried, founder and chief executive officer of FTX, said in a phone interview. "When we think about what FTX represents, we want to be the best product that is out there." FTX, with 29-year-old Mr Bankman-Fried at the helm, has become one of the world's largest crypto exchanges since its launch just two years ago. Mr Bankman-Fried said he has spoken with others in the past about possible partnerships, but something ...

SeaPRwire

US stocks edge to records as consumer confidence rises

elean
2 minutes

NEW YORK (AFP) - Wall Street stocks edged higher on Tuesday (June 29), adding to recent records, as US consumer confidence continued to improve while investors grapple with the latest coronavirus worries. US consumer confidence surged in June to its highest point since the start of the pandemic, propelled by the improved outlook on jobs and business conditions, according to The Conference Board. "Low virus transmission, vaccinations, and expanded reopenings made consumers much more confident," Mr Oren Klachkin of Oxford Economics said in an analysis. "Consumers are coming out of their shell." But analysts are keeping an eye on Covid-19 as the Delta strain of the virus prompts fresh restrictions in Australia and other countries. The tech-rich Nasdaq Composite Index again led the market, climbing 0.2 per cent to 14,528.33, its fifth record finish in six sessions. The broad-based S&P 500 also eked out a record, gaining less than 0.1 per cent to 4,291.80, while the Dow Jones Industrial Average finished up by a hair at 34,292.29. United Airlines lost 0.7 per cent following a choppy session after it announced a record new plane order. United plans to acquire 270 aircraft consisting of 20...

ACN Newswire
Read More

雅各臣公布二零二一财年全年业绩

tallulah
1 minute

HONG KONG, Jun 29, 2021 - (亚太商讯 via SEAPRWire.com) - 从事基础药物、专科药物及品牌医疗保健品研发、生产、市场推广及销售的领先企业─雅各臣科研制药有限公司（「雅各臣」或「公司」；股份代号：2633 )今天公布公司及其附属公司（统称「集团」）于截至二零二一年三月三十一日止年度（「二零二一财年」或「报告期」）的全年业绩。于报告期内，因应疫情实施的各种社交距离措施及出行限制，经济及零售消费市场受严重影响。集团于报告期内录得总收益1,445.9百万港元，较去年轻微减少8.0%。随着推行舒缓及成本节省措施，集团录得权益持有人应占溢利173.7百万港元，同比减少19.4%。董事会建议宣派末期股息每股1.5港仙（二零二零财年：每股2.5港仙），连同已派付的中期股息每股0.8港仙，以及于二零二一年二月五日向公司股东以实物分派形式宣派的特别中期股息，基准为每持有8股本公司股份获分派1股健倍苗苗(保健)有限公司（「健倍苗苗」；股份代号：2161）股份，按每股健倍苗苗股份1.20港元的价格计算，特别中期股息相当于约每股15港仙的分派，二零二一财年的股息总额为每股17.3港仙（二零二零财年股息总额：每股4.5港仙）。公营界别非专利药业务稳步增长于报告期内，集团非专利药业务的收益为1,048.8百万港元。尽管公营界别稳步增长，但因疫情推行的防感染控制措施严重打击私营界别，因此其增长被私营界别低迷的销售趋势所抵销。集团供应的若干治疗类别产品录得稳健增长，其中公营界别的口服糖尿药及肠胃科类别分别录得28.3%及26.0%增长，主要得益于招标业务以及该等基础药物在各疾病管理类别中的使用量增加。此外，集团的血管紧张素转化酶抑制剂(angiotensin-converting enzyme inhibitor)类别及血管紧张素Ⅱ拮抗剂(angiotensin II antagonist)类别的心血管产品分别录得62.2%及33.6%的强劲销售增长，公营界别降压药的消费亦有所增长。集团于报告期内推出多项新产品，包括三氧化二砷口服液(Arsenic Trioxide Oral Solution)、双氢可待因片(Dihydrocodeine Tablet)、培哚普利片(Perindopril Tablet)、阿托莫西汀胶囊(Atomoxetine Capsule)、瑞舒伐他汀片(Rosuvastatin Tablet)及羟氯喹片(Hydroxychloroquine Tablet)。其中，三氧化二砷口服液为首项于香港成功注册的三氧化二砷产品，批准用于治疗急性早幼粒细胞白血病。集团亦已与欧洲及南韩知名制药商签订合共15种专科药物的区域授权协议，涵盖中枢神经系统、抗感染、肠胃科及其他治疗类。品牌医疗保健业务表现强韧集团的品牌医疗保健业务于报告期内的总收益...

ACN Newswire
Read More

健倍苗苗（保健）公布二零二一财年全年业绩

tallulah
1 minute

HONG KONG, Jun 29, 2021 - (亚太商讯 via SEAPRWire.com) - 健倍苗苗（保健）有限公司（「健倍苗苗」或「集团」；股份代号：2161）为香港领先的品牌医疗保健品推广商及分销商，集团今天公布自二零二一年二月五日于香港联合交易所有限公司主板分拆上市后的首份全年业绩。面对2019冠状病毒病疫情（「疫情」）带来前所未有的挑战，集团于截至二零二一年三月三十一日止年度（「报告期」）之总收益仍录得397.2百万港元，较去年增长4.1％。撇除一次性上市开支，经调整纯利*较去年上升13.3%至54.6百万港元。每股基本盈利为2.78港仙。强大的组合带动业务表现强韧集团强劲而广泛的产品组合由品牌药、品牌中药及健康保健品分部组成。品牌中药业务的销售收益达210.9百万港元，显著增长14.6%，主要由海天浓缩中药颗粒产品销售有力的表现，加上飞鹰活络油于中国的销售渗透率有所提升从而实现16.8%收益增长所带动。于报告期内，集团透过加入第三方品牌安宫牛黄丸及灵芝胞子丰富其品牌中药产品组合，以发掘中国市场巨大的潜在需求。 于报告期内，品牌药业务录得收益134.5百万港元，较去年下跌5.4%。在各个知名品牌中，尽管疫情对儿童到医院及眼科医生就诊造成阻碍，但AIM亚妥明眼药水仍实现9.7%的适度增长。受疫情影响，健康保健品于报告期内的销售收益轻微下降6.3%。该业务分部涵括针对消费者日常健康及保健的补充品、个人护理产品及其他诊断工具。其中，个人卫生及感染控制产品的需求急升。作为进一步强化健康保健产品组合策略的一部分，集团推出健康保健品品牌 - Dr. Freeman醫臣®产品系列，以回应市场对感染控制及个人卫生产品日益增长的需求。开设线上旗舰店为发掘中国跨境电子商务快速增长的潜力，集团已于天猫卖场型旗舰店及京东国际开放平台店铺开设自营线上旗舰店，为中国消费者提供多达40种以上的优质品牌保健产品。集团亦于深圳成立自有电子商务团队，为自营线上旗舰店提供直接营运及客户服务支援。与满贯集团成立合资公司集团已与满贯集团控股有限公司 (「满贯集团」；股份代号：3390）订立合作协议，希望藉此充分利用和发挥双方在中成药、中医药医疗保健及健康补充品市场的协同效益。通过是次战略合作，集团将透过双方新成立的合资公司研发及/或制造自有品牌产品，以迎合市场趋势及消费者需求，并就该等产品提供分销、策略营销及销售支持。自有品牌产品预期将于二零二一年第三季度推出。健倍苗苗（保健）行政总裁黄一伟先生表示：「二零二零年开局艰难，面对疫情，我们矢志不渝，积极应对2019冠状病毒病对业务造成的影响。面对挑战重重的市场环境，我们的团队在推行业务策略方面着实付出了巨大努力，同时有赖集团多元化的产品组合及地域市场，整体业务仍然表现强韧。展望未来，我们将继续提升线下及线上的商业实力，透过丰富产品...

ACN Newswire
Read More

Jacobson Pharma Announces FY2021 Annual Results

indie
6 minutes

HONG KONG, Jun 29, 2021 - (ACN Newswire via SEAPRWire.com) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaging in the research, development, production, marketing and sale of essential medicines, specialty drugs and branded healthcare products, today announced the annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2021 (the "FY2021" or the "Reporting Period").During the Reporting Period, the economy was hit hard by the pandemic with retail consumption stalled due to various social distancing measures and travel restrictions. At the continual impact of the pandemic on its businesses, the Group made total revenue of HK$1,445.9 million in the Reporting Period, dropped narrowly by 8.0% against the previous year. Mitigated by the impact relief and cost-saving measures, profit attributable to shareholders softened by 19.4% to HK$173.7 million.The Board has recommended payment of a final dividend of HK1.5 cents per share (FY2020: HK2.5 cents per share). Including the interim dividend of HK0.8 cent per share already paid and a special interim dividend made by the Comp...

ACN Newswire
Read More

JBM Healthcare Announces FY2021 Annual Results

indie
5 minutes

HONG KONG, Jun 29, 2021 - (ACN Newswire via SEAPRWire.com) - JBM (Healthcare) Limited ("JBM Healthcare" or the "Group"; Stock Code: 2161), a leading branded healthcare products marketer and distributor in Hong Kong, has announced today the first annual results of the Group after its spin-off listing on the Main Board of The Stock Exchange of Hong Kong Limited on 5 February 2021. Despite the unprecedented challenges due to the COVID-19 pandemic, the Group posted a total revenue of HK$397.2 million during the year ended 31 March 2021 ("Reporting Period"), representing a growth of 4.1% from last year. Before taking into account the one-off listing expenses, the adjusted net profit* increased by 13.3% to HK$54.6 million when compared with last year. Basic earnings per share was HK2.78 cents.Resilient Performance Driven by Strong Product PortfolioJBM Healthcare carries a robust and broad portfolio of branded healthcare products in the segments of branded medicines, proprietary Chinese medicines, and health and wellness products.As for the proprietary Chinese medicines ("PCM") business, sales revenue notably increased by 14.6% to HK$210.9 million, driven by the buoyant performance of Hoi...

ACN Newswire
Read More

解锁招股书源代码，透露出YesAsia怎样的业务增长故事？

tallulah
1 minute

HONG KONG, Jun 29, 2021 - (亚太商讯 via SEAPRWire.com) - 关于消费文化与时尚消费，鲍德里亚《消费文化》认为，随着商品经济发展，“物品”这一概念发生了内涵型的转变，也就是说物品“必须具有一个外在于它并作为意义指涉的关系结构，物品本身被组织为表达这个意义体系的要素”。当附带亚洲文化的时装与生活时尚、美容及娱乐产品走向世界，会产生怎样的火花？关于这个问题，正在IPO节拍上的YesAsia给出了答案。透过其招股书上显示的关键细节，或许我们能够对YesAsia的业务基本盘、未来成长性有了更深一层次的认识。一、扎实的业务基本盘：关键节点增长态势显著对于一家即将IPO的企业而言，进行价值评估最直接的指针其实就是业务的增长性以及最近几年的财务状况。从业务层面来看，YesStyle平台销售美容及时装与生活时尚产品；AsianBeautyWholesale平台通过B2B管道销售美容产品；YesAsia平台主要通过B2C管道来销售娱乐产品。招股书显示，截止2018年度至2020年度，YesAsia收益分别为8536.4万美元、1.18亿美元及1.73亿美元。对应的毛利方面，分别为2906.7万美元、3764.8万美元及6187.1万美元; 净利分别为399.2万美元、336.9万美元及1122.0万美元。不难发现，YesAsia业务增长势头明显。其中，毛利率方面，直接反映公司的赚钱水平，YesAsia毛利呈逐年上升的趋势，这其实是公司盈利能力不断增强的体现。增速高且稳定的营收，体现出YesAsia强劲的发展动能。从具体业务层面来看，时装和生活时尚及美容产品占总收入的比重不断提升，从2018年的85.2%逐年提升至2020年的94.2%，尤其是旗下的YesStyle表现更是抢眼。从用户层面来看，根据智通财经APP的观测，YesAsia的平均月度活跃用户总数由2019年末的390万人，增长至2020年末的590万人，增速非常明显。各项关键数据的增长表现说明YesAsia商业模式发展规划的正确性，企业已经得到市场的认可。现在确定性明显很强的公司，未来势必还会有更好的增长。如今，YesAsia其实已经形成了自己的内生性增长引擎，忠诚活跃的客户群推动业务生态圈良性循环，业务基本盘稳健，未来发展具备较强的确定性，具备价值投资的基础。二、长期优势凸显：高价值投资的赛道选择评价一家公司是否具备长期价值，离不开以下两个维度：行业成长空间以及企业自身的商业模式表现。从行业空间来看，作为目前收入的重要来源，YesStyle时装与生活时尚、美容及娱乐产品都是具有文化融合能力的消费品，突出亚洲一些特色文化的可视化表达，最大化地去感染不同区域文化的人群，最终把亚洲故事以产品的形式推向世界。这种具备文化附加值的商品，未来也具备极高的想象空间。而且，从理论上讲，Y...